Braveheart Bio — Third Quarter 2026 Earnings Summary

Braveheart Bio reported third-quarter 2026 financial results showing a net loss of $26.5 million and cash reserves of $503.5 million, sufficient to fund operations into 2029. The company presented 52-week clinical data for its lead candidate BHB-1893 at the AHA Scientific Sessions 2026, demonstrating improved oxygen uptake and heart function in patients with obstructive hypertrophic cardiomyopathy. Development strategies have been updated to include the enrolling LIONHEART-HCM Phase 3 trial, a planned NOBLEHEART-HCM Phase 3 trial for non-obstructive patients in the first half of 2027, and a fixed-dose TRUEHEART-HCM Phase 2b study. Additionally, partner Hengrui Pharma has completed enrollment in its Phase 3 trial in China, with topline results expected in early 2027.